*This article was originally published for ROTY subscribers on Jan. 15, but has been updated where necessary. Despite the recent rebound, the story remains in early innings with substantial upside potential ahead should management continue to execute with the Dextenza launch and progression of early-stage assets in the clinic.
Shares of Ocular Therapeutix (OCUL) have risen by 57% since my initial recommendation in June last year, where we highlighted significant insider buying and value proposition of its lead product Dextenza. Shares have risen by 13% since my July update.
My initial